Table 2. Corrleation of FHIT, PCNA and EGFR expression in nonproliferative and proliferative breast lesions.
| Category | Grade |
Expression status (no. of cases)
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FHIT | ↔ | ↔ | ↓ | ↓ | FHIT | ↔ | ↓ | ↓ | ↔ | |||
| PCNA | ↑ | ↓ | ↑ | ↓ | ||||||||
| EGFR | ↑ | ↑ | ↔ | ↔ | ||||||||
| BBD | (a) Nonproliferative | Normal | 24 | 36 | 0 | 0 | ND | ND | ND | ND | ||
| Inflammation | 6 | 7 | 0 | 0 | ND | ND | ND | ND | ||||
| Cyst | 3 | 1 | 0 | 0 | ND | ND | ND | ND | ||||
| Metaplasia | 14 | 4 | 0 | 0 | ND | ND | ND | ND | ||||
| Blind duct adenosis | 35 | 25 | 0 | 0 | ND | ND | ND | ND | ||||
| Hyperplasia (usual type) | 17 | 7 | 0 | 0 | ND | ND | ND | ND | ||||
| Fibroadenoma | 60 | 24 | 0 | 0 | ND | ND | ND | ND | ||||
| (b) Proliferative | Papilloma | 16 | 9 | 0 | 0 | ND | ND | ND | ND | |||
| without atypia | Sclerosing adenosis | 29 | 7 | 0 | 0 | ND | ND | ND | ND | |||
| Hyperplasia (moderate) | 34 | 13 | 1 | 0 | 0 | 0 | 1 | 3 | ||||
| Hyperplasia (florid) | 14 | 3 | 2 | 0 | 1 | 0 | 0 | 14 | ||||
| (c) Proliferative | ADH/ALH | 8 | 2 | 1 | 0 | 0 | 1 | 0 | 5 | |||
| with atypia | ||||||||||||
| Carcinoma | (a) In situ | LCIS | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | ||
| DCIS | 8 | 0 | 4 | 0 | 2 | 0 | 3 | 6 | ||||
| (b) Invasive | 18 | 2 | 14 | 0 | 11 | 6 | 7 | 8 | ||||
| Total | 289 | 140 | 22 | 0 | 14 | 7 | 11 | 39 | ||||
| n=451 | n=71 | |||||||||||
↔=normal level of expression; ↑=overexpression; ↓=underexpression; ND=not done.